However, as the rate and magnitude of PSA decline following definitive RT for prostate cancer seem to be correlated with clinical outcomes [48–50], the median value of PSA nadir at 3 months in our series indicates an optimal treatment response at least at a very early timepoint. The gene discussed is KLK3; the disease is Familial prostate cancer.